EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain

Low- or no-opioid pain control is possible with EXPAREL

EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. When injected into the surgical site, EXPAREL turns off the body’s pain signals, numbing the area where surgery has occurred for several days following the procedure. To date, EXPAREL has been used in over 8 million patients.1

EXPAREL is the only non-opioid, single-dose, long-acting local anesthetic approved for infiltration, field block, and interscalene brachial plexus nerve block.

Visit EXPAREL.com to learn more

EXPAREL infiltration provides significant long-lasting pain control while reducing opioid use*

EXPAREL vs bupivacaine HCI in total knee arthroplasty (TKA)2

fewerOpioids

With significantly better pain control through 48 hours (P < 0.04)

Results from an EXPAREL Phase 4, double-blind, randomized controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in TKA. Primary endpoints: area under the curve of visual analog scale pain intensity scores 12–48 hours postsurgery; total opioid consumption 0–48 hours postsurgery. Rescue opioids for pain were available upon patient request.Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness and muscle spasms.

In a TKA study of EXPAREL vs bupivacaine HCI2

1 OUT OF 10 PATIENTS WHO RECEIVED EXPAREL WERE OPIOID FREE

THROUGH DAY 2 & 3 POSTSURGERY

10%with exparel

(n=70)

vs

(P<0.01)

0%WITH BUPIVACAINE HCI

(n=69)

Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, muscle spasms, vomiting.

EXPAREL vs placebo in a soft-tissue surgery3,4

fewerOpioidsPurple

With significantly better pain control through 72 hours (P = 0.0006†)

 

Results from a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial that evaluated the safety and efficacy of 266mg (20ml) EXPAREL in 186 patients undergoing 2- or 3-column excisional hemorrhoidectomy. Primary endpoint: cumulative pain score reflected in area under the curve of numeric rating scale through 72 hours. Placebo was preservative-free saline for injection. Opioid rescue medication (up to 10 mg IM morphine) was available to all patients.

†Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio.

In a soft tissue study of EXPAREL vs placebo3

3 out of 10 PATIENTS WHO RECEIVED EXPAREL were opioid free

Through day 3 postsurgery

28% with exparel

(n=95)

vs

(P<0.0081)

10% with placebo

(n=94)

Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness, and muscle spasms.

Excellent results with EXPAREL as a single-dose interscalene brachial plexus nerve block

Significant postsurgical pain relief that lasts 48 hours with EXPAREL

VAS pain intensity scores with interscalene brachial plexus nerve block5

efficacy

Primary endpoint was area under the curve (AUC) of the visual analog scale (VAS) pain intensity scores; 136 vs 254 (LSMD -118) for EXPAREL and placebo, respectively5

PACU=postanesthesia care unit. LSMD=least squares mean difference. Results from a phase 3 double-blind, randomized, controlled trial that compared the postsurgical analgesia efficacy, safety, and pharmacokinetics of EXPAREL 133 mg (10 mL) and placebo in patients undergoing total shoulder arthroplasty or rotator cuff repair. Primary and secondary endpoints: pain intensity through 48 hours postsurgery, as measured by area under the curve (AUC) of visual analog scale (VAS) pain intensity scores and total postsurgical opioid consumption. Rescue opioids for pain were available upon patient request.

78% reduction in opioids through 48 hours

Postsurgical opioid consumption6

efficacy

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the clinical trials

Visit EXPAREL.com to learn more